Androgen Deprivation Therapy for Localised Prostate Cancer Not Associated With Improved Survival
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Androgen Deprivation Therapy for Localised Prostate Cancer Not Associated With Improved Survival

CHICAGO -- July 8, 2008 -- Primary androgen deprivation therapy (PADT) is not associated with improved survival for elderly men with localised prostate cancer, compared to conservative management of the disease, according to a study in the July 9 issue of JAMA.

Grace L. Lu-Yao, PhD, Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey, and colleagues, assessed the association between PADT and disease-specific survival and overall survival in 19,271 men with T1-T2 prostate cancer who were diagnosed between 1992 and 2002.

The patients, aged 66 years or older, did not receive definitive local therapy for prostate cancer. Of the patients, 7,867 (41%) received PADT, and 11,404 were treated with conservative management, not including PADT.

Patients were followed-up for all-cause mortality through December 2006, and for prostate cancer-specific mortality through December 2004. During this follow-up period, there were 1,560 prostate cancer deaths and 11,045 deaths from all causes.

The researchers found that use of PADT for localised prostate cancer was associated with lower 10-year prostate cancer-specific survival (80.1% vs 82.6%) and no increase in 10-year overall survival compared with conservative management.

However, in a prespecified subset analysis, PADT use in men with poorly differentiated cancer was associated with improved 10-year prostate cancer-specific survival (59.8% vs 54.3%) but not overall survival (17.3% vs 15.3%).

"The significant adverse effects and costs associated with PADT, along with our finding of a lack of overall survival benefit, suggest that clinicians should carefully consider the rationale for initiating PADT in elderly patients with T1-T2 prostate cancer," the authors wrote.

SOURCE: JAMA

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities